Point-of-Care/Rapid Diagnostics Market by Testing (Glucose, Lipids, HbA1c, HCV, HIV, Influenza, Urinalysis, Hematology, Cancer, Pregnancy, PT/INR), Platform (Lateral Flow, Immunoassay), Mode (Prescription, OTC), End-User - Global Forecast to 2022

  • ID: 4464393
  • Report
  • Region: Global
  • 228 Pages
  • Markets and Markets
1 of 4
Point-of-Care/Rapid Diagnostics Market worth 38.13 Billion USD by 2022

FEATURED COMPANIES

  • Abbott Laboratories
  • Accubiotech
  • Chembio Diagnostics
  • Danaher Corporation
  • EKF Diagnostics
  • Johnson & Johnson
  • MORE

“The point-of-care diagnostics market projected to grow at a CAGR of 10.0%.”

The global point-of-care diagnostics market is projected to reach USD 38.13 billion by 2022 from USD 23.71 billion in 2017, at a CAGR of 10.0%. High prevalence of infectious diseases in developing countries, increasing incidence of target diseases, and increasing inclination toward home healthcare across the globe are the factors expected to drive the market during the study period. However, the lack of alignment with definitive central lab methods, certain disadvantages of POC testing over central lab methods, and the reluctance among physicians to change existing diagnostic practices are the key factors that are limiting the growth of this market.

“The glucose monitoring products segment is expected to command the largest share of the POC diagnostics market in 2017.”

On the basis of product, the glucose monitoring products segment is expected to command the largest share of the global POC diagnostics market in 2017. The large share of this segment can be attributed to the growing incidence and prevalence of diabetes across the globe and rising preference for home glucose testing.

“The molecular diagnostics segment is expected to be the fastest-growing segment during the forecast period.”

On the basis of platform, the market is segmented into lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. The molecular diagnostics segment is expected to be the fastest-growing segment during the forecast period. Growing advancements in technology and increasing initiatives of market players for developing POC molecular diagnostic products is propelling the demand for molecular diagnostics.
 
“Asia Pacific is expected grow at the highest CAGR during the forecast period.”

Geographically, the point-of-care diagnostics market is segmented into North America, Europe, Asia Pacific, and RoW. Asia Pacific is expected to register the highest growth rate during the forecast period due to the growing initiatives by market players, increasing patient population base, and rising number of partnerships and joint ventures in this region.

Breakdown of supply-side primary interviews:

  • By Company Type - Tier 1 - 35%, Tier 2 - 45% and Tier 3 - 20%
  • By Designation - - C level - 15%, Director level - 30%, Others - 55%
  • By Region - North America - 45%, Europe - 20%, APAC - 30%, RoW - 5%

The major players of the point-of-care diagnostics market are Abbott (US), Roche (Switzerland), Siemens (Germany), Danaher (US), Becton, Dickinson, and Company (US), Johnson & Johnson (US), Instrumentation Laboratory (US), PTS Diagnostics (US), Quidel (US), Chembio (US), Sekisui Diagnostics (US), Nova (US), EKF Diagnostics (UK), AccuBioTech (China), and Trinity Biotech (US).

Research Coverage:

This report studies the point-of-care diagnostics market based on product, platform, mode, end user, and region. The report also studies factors affecting market growth, it analyzes opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends. The report forecasts the revenue of market segments with respect to the four key regions and respective countries.

Reasons to Buy the Report:

From an insights perspective, this research report has focused on various levels of analysis- market ranking analysis of top players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging segments of the point-of-care diagnostics market, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help firms garner greater market shares.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Accubiotech
  • Chembio Diagnostics
  • Danaher Corporation
  • EKF Diagnostics
  • Johnson & Johnson
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.4 Markets Covered
1.4.1 Years Considered for the Study
1.5 Currency
1.6 Limitations
1.7 Stakeholders

2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Secondary Sources
2.1.2 Primary Data
2.1.2.1 Primary Sources
2.1.2.2 Key Industry Insights
2.1.3 Market Size Estimation Methodology
2.1.3.1 Bottom-Up Approach
2.1.3.2 Top-Down Approach
2.1.4 Research Design
2.1.5 Market Data Validation and Triangulation
2.1.6 Assumptions for the Study

3 Executive Summary
3.1 Introduction

4 Premium Insights
4.1 POC Diagnostics: Market Overview
4.2 POC Diagnostics Market, By Platform
4.3 Geographic Analysis: POC Diagnostics Market, By End User and Region
4.4 POC Diagnostics Market, By Product
4.5 POC Diagnostics Market, By Prescription Mode
4.6 Geographic Snapshot of the POC Diagnostics Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Infectious Diseases in Developing Countries
5.2.1.2 Increasing Incidence of Target Diseases
5.2.1.3 Rising Usage of Home-Based POC Devices
5.2.1.4 Growing Government Support
5.2.1.5 Technological Advancements and New Product Launches
5.2.1.6 Growing Number of Regulatory Approvals for Novel Immunoassay Techniques
5.2.1.7 Shortage of Skilled Laboratory Technicians
5.2.1.8 Rising Number of Clia-Waived POC Tests
5.2.2 Restraints
5.2.2.1 Product Recalls: Hampering User Confidence
5.2.2.2 Pricing Pressure Owing to Reimbursement Cuts and Budget Constraints
5.2.2.3 Stringent and Time-Consuming Regulatory Policies are Significantly Increasing Gestation Period for Product Launches
5.2.3 Opportunities
5.2.3.1 Growth Opportunities in Emerging Markets
5.2.3.2 Healthcare Decentralization - Converting Lab Tests to POC Tests
5.2.3.3 Increasing Number of Conferences and Events
5.2.3.4 POC Tests With Multiplexing Capabilities
5.2.4 Challenges
5.2.4.1 Lack of Alignment With Definitive Central Lab Methods
5.2.4.1.1 Disadvantages of POC Testing Over Central Lab Methods
5.2.4.2 Inadequate Knowledge About the Use of POC Devices in Professional Settings
5.2.4.3 Reluctance Towards Changing Existing Diagnostic Practices
5.2.4.4 High Cost of Devices
5.2.5 Emerging Applications of Point-of-Care Testing
5.2.5.1 Sepsis Biomarkers
5.2.5.2 Stroke Markers
5.2.5.3 Thyroid Testing
5.2.5.4 Dna Testing
5.2.5.5 Endocrine Testing

6 Point-of-Care Diagnostics Market, By Product
6.1 Introduction
6.2 Glucose Monitoring Products
6.2.1 Strips
6.2.2 Meters
6.2.3 Lancets & Lancing Devices
6.3 Cardiometabolic Testing Products
6.3.1 Cardiac Marker Testing Products
6.3.2 Blood Gas/Electrolytes Testing Products
6.3.3 HBA1C Testing Products
6.4 Infectious Disease Testing Products
6.4.1 Influenza Testing Products
6.4.2 HIV Testing Products
6.4.3 Hepatitis C Testing Products
6.4.4 Sexually Transmitted Disease (STD) Testing Products
6.4.5 Healthcare-Associated Infection (HAI) Testing Products
6.4.6 Respiratory Infection Testing Products
6.4.7 Tropical Disease Testing Products
6.4.8 Other Infectious Disease Testing Products
6.5 Coagulation Testing Products
6.5.1 PT/INR Testing Products
6.5.2 Activated Clotting Time (ACT/APTT) Testing Products
6.6 Pregnancy and Fertility Testing Products
6.6.1 Pregnancy Testing Products
6.6.2 Fertility Testing Products
6.7 Tumor/Cancer Marker Testing Products
6.8 Urinalysis Testing Products
6.9 Cholesterol Testing Products
6.10 Hematology Testing Products
6.11 Drugs-of-Abuse Testing Products
6.12 Fecal Occult Testing Products
6.13 Other POC Products

7 Point-of-Care Diagnostics Market, By Platform
7.1 Introduction
7.2 Lateral Flow Assays (Immunochromatography Tests)
7.3 Dipsticks
7.4 Microfluidics
7.5 Molecular Diagnostics
7.6 Immunoassays

8 Point-of-Care Diagnostics Market, By Prescription Mode
8.1 Introduction
8.2 Prescription-Based Testing
8.3 OTC Testing

9 Point-of-Care Diagnostics Market, By End User
9.1 Introduction
9.2 Professional Diagnostic Centers
9.2.1 Outpatient Healthcare & Ambulatory Care Settings
9.2.2 Hospitals/Critical Care Centers
9.3 Home Care
9.4 Research Laboratories
9.5 Other End Users

10 Point-of-Care Diagnostics Market, By Region
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Rest of Europe (RoE)
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Rest of the World (RoW)
10.5.1 Latin America
10.5.2 Middle East & Africa

11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis, 2016
11.3 Competitive Scenario and Trends
11.3.1 Product Launches
11.3.2 Agreements, Partnerships, and Collaborations
11.3.3 Product Approvals
11.3.4 Acquisitions

12 Company Profiles
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 Abbott Laboratories
12.2 Accubiotech
12.3 Becton, Dickinson, and Company (BD)
12.4 Chembio Diagnostics
12.5 Danaher Corporation
12.6 EKF Diagnostics
12.7 Instrumentation Laboratory (A Werfen Company)
12.8 Johnson & Johnson
12.9 Nova Biomedical
12.10 PTS Diagnostics (A Part of Sinocare Inc.)
12.11 Quidel
12.12 Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche Ltd.)
12.13 Sekisui Diagnostics
12.14 Siemens
12.15 Trinity Biotech

*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

13 Appendix
13.1 Discussion Guide
13.2 Knowledge Store
13.3 Introducing RT: Real-Time Market Intelligence
13.4 Available Customizations
13.5 Related Reports
13.6 Author Details

List of Tables:
Table 1 Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 2 Rapid Diagnostic Market for Glucose Monitoring Products, By Type, 2015–2022 (USD Million)
Table 3 Glucose Monitoring Meters Market, By Region, 2015–2022 (Units)
Table 4 Global Market for Glucose Monitoring Products, By Region, 2015–2022 (USD Million)
Table 5 Rapid Diagnostic Market for Cardiometabolic Testing Products, By Type, 2015–2022 (USD Million)
Table 6 Point-of-Care Diagnostics Market for Cardiometabolic Testing Products, By Region, 2015–2022 (USD Million)
Table 7 Cardiac Marker Testing Products Market, By Region, 2015–2022 (USD Million)
Table 8 Cardiac Marker Testing Products Market, By Region, 2015–2022 (Units)
Table 9 Blood Gas/Electrolytes Testing Products Market, By Region, 2015–2022 (USD Million)
Table 10 Blood Gas/Electrolytes Testing Analyzers Market, By Region, 2015–2022 (Units)
Table 11 HBA1C Testing Products Market, By Region, 2015–2022 (USD Million)
Table 12 Point-of-Care Diagnostics Market for Infectious Disease Testing Products, By Type, 2015–2022 (USD Million)
Table 13 Rapid Diagnostic Market for Infectious Disease Testing Products, By Region, 2015–2022 (USD Million)
Table 14 Global Market for Influenza Testing Products, By Region, 2015–2022 (USD Million)
Table 15 Influenza Testing Analyzers Market, By Region, 2015–2022 (Units)
Table 16 HIV Testing Products Market, By Region, 2015–2022 (USD Million)
Table 17 HIV Testing Analyzers Market, By Region, 2015–2022 (Units)
Table 18 Hepatitis C Testing Products Market, By Region, 2015–2022 (USD Million)
Table 19 Hepatitis C Testing Analyzers Market, By Region, 2015–2022 (Units)
Table 20 STD Testing Products Market, By Region, 2015–2022 (USD Million)
Table 21 Healthcare-Associated Infection Testing Products Market, By Region, 2015–2022 (USD Million)
Table 22 Respiratory Infection Testing Products Market, By Region, 2015–2022 (USD Million)
Table 23 Tropical Disease Testing Products Market, By Region, 2015–2022 (USD Million)
Table 24 Other Infectious Disease Testing Products Market, By Region, 2015–2022 (USD Million)
Table 25 Point-of-Care Diagnostics Market for Coagulation Testing Products, By Type, 2015–2022 (USD Million)
Table 26 Rapid Diagnostic Market for Coagulation Testing Products, By Region, 2015–2022 (USD Million)
Table 27 Coagulation Testing Analyzers Market, By Region, 2015–2022 (Units)
Table 28 PT/INR Testing Products Market, By Region, 2015–2022 (USD Million)
Table 29 ACT/APTT Testing Products Market, By Region, 2015–2022 (USD Million)
Table 30 Point-of-Care Diagnostics Market for Pregnancy and Fertility Testing Products, By Type, 2015–2022 (USD Million)
Table 31 Rapid Diagnostic Market for Pregnancy and Fertility Testing Products, By Region, 2015–2022 (USD Million)
Table 32 Pregnancy Testing Products Market, By Region, 2015–2022 (USD Million)
Table 33 Fertility Testing Products Market, By Region, 2015–2022 (USD Million)
Table 34 Point-of-Care Diagnostics Market for Tumor/Cancer Marker Testing Products, By Region, 2015–2022 (USD Million)
Table 35 Rapid Diagnostic Market for Urinalysis Testing Products, By Region, 2015–2022 (USD Million)
Table 36 Urinalysis Testing Analyzers Market, By Region, 2015–2022 (Units)
Table 37 Global Market for Cholesterol Testing Products, By Region, 2015–2022 (USD Million)
Table 38 Cholesterol Testing Analyzers Market, By Region, 2015–2022 (Units)
Table 39 Rapid Diagnostic Market for Hematology Testing Products, By Region, 2015–2022 (USD Million)
Table 40 Hematology Testing Analyzers Market, By Region, 2015–2022 (Units)
Table 41 Point-of-Care Diagnostics Market for Drugs-of-Abuse Testing Products, By Region, 2015–2022 (USD Million)
Table 42 Rapid Diagnostic Market for Fecal Occult Testing Products, By Region, 2015–2022 (USD Million)
Table 43 Point-of-Care Diagnostics Market for Other POC Products, By Region, 2015–2022 (USD Million)
Table 44 POC Diagnostics Market, By Platform, 2015–2022 (USD Million)
Table 45 Lateral Flow Assays Market, By Region, 2015–2022 (USD Million)
Table 46 Dipsticks Market, By Region, 2015–2022 (USD Million)
Table 47 Microfluidics Market, By Region, 2015–2022 (USD Million)
Table 48 Molecular Diagnostics Market, By Region, 2015–2022 (USD Million)
Table 49 Immunoassays Market, By Region, 2015–2022 (USD Million)
Table 50 Point-of-Care Diagnostics Market, By Prescription Mode, 2015–2022 (USD Million)
Table 51 Prescription-Based Testing Market, By Region, 2015–2022 (USD Million)
Table 52 OTC Testing Products Market, By Region, 2015–2022 (USD Million)
Table 53 Global Market, By End User, 2015–2022 (USD Million)
Table 54 Rapid Diagnostic Market for Professional Diagnostic Centers, By Type, 2015–2022 (USD Million)
Table 55 Point-of-Care Diagnostics Market for Professional Diagnostic Centers, By Region, 2015–2022 (USD Million)
Table 56 Rapid Diagnostic Market for Outpatient Healthcare & Ambulatory Care Settings, By Region, 2015–2022 (USD Million)
Table 57 Global Market for Hospitals/Critical Care Centers, By Region, 2015–2022 (USD Million)
Table 58 Point-of-Care Market for Home Care, By Region, 2015–2022 (USD Million)
Table 59 Rapid Diagnostic Market for Research Laboratories, By Region, 2015–2022 (USD Million)
Table 60 Point-of-Care Diagnostics Market for Other End Users, By Region, 2015–2022 (USD Million)
Table 61 Rapid Diagnostic Market, By Region, 2015–2022 (USD Million)
Table 62 North America: Point-of-Care Diagnostics Market, By Country, 2015–2022 (USD Million)
Table 63 North America: Market, By Product, 2015–2022 (USD Million)
Table 64 North America: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 65 North America: Market, By Platform, 2015–2022 (USD Million)
Table 66 North America: Rapid Diagnostic Market, By End User, 2015–2022 (USD Million)
Table 67 US: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 68 US: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 69 US: Market, By Platform, 2015–2022 (USD Million)
Table 70 US: Market, By End User, 2015–2022 (USD Million)
Table 71 Canada: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 72 Canada: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 73 Canada: Market, By Platform, 2015–2022 (USD Million)
Table 74 Canada: Market, By End User, 2015–2022 (USD Million)
Table 75 Europe: Point-of-Care Diagnostics Market, By Country, 2015–2022 (USD Million)
Table 76 Europe: Market, By Product, 2015–2022 (USD Million)
Table 77 Europe: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 78 Europe: Market, By Platform, 2015–2022 (USD Million)
Table 79 Europe: Rapid Diagnostic Market, By End User, 2015–2022 (USD Million)
Table 80 Germany: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 81 Germany: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 82 Germany: Market, By Platform, 2015-2022 (USD Million)
Table 83 Germany: Market, By End User, 2015–2022 (USD Million)
Table 84 France: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 85 France: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 86 France: Market, By Platform, 2015–2022 (USD Million)
Table 87 France: Market, By End User, 2015–2022 (USD Million)
Table 88 UK: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 89 UK: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 90 UK: Market, By Platform, 2015–2022 (USD Million)
Table 91 UK: Rapid Diagnostic Market, By End User, 2015–2022 (USD Million)
Table 92 RoE: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 93 RoE: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 94 RoE: Market, By Platform, 2015–2022 (USD Million)
Table 95 RoE: Market, By End User, 2015–2022 (USD Million)
Table 96 APAC: Point-of-Care Diagnostics Market, By Country, 2015–2022 (USD Million)
Table 97 APAC: Market, By Product, 2015–2022 (USD Million)
Table 98 APAC: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 99 APAC: Market, By Platform, 2015–2022 (USD Million)
Table 100 APAC: Market, By End User, 2015–2022 (USD Million)
Table 101 Japan: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 102 Japan: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 103 Japan: Market, By Platform, 2015–2022 (USD Million)
Table 104 Japan: Market, By End User, 2015–2022 (USD Million)
Table 105 China: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 106 China: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 107 China: Market, By Platform, 2015–2022 (USD Million)
Table 108 China: Market, By End User, 2015–2022 (USD Million)
Table 109 India: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 110 India: Market, By Prescription Mode, 2015-2022 (USD Million)
Table 111 India: Market, By Platform, 2015–2022 (USD Million)
Table 112 India: Rapid Diagnostic Market, By End User, 2015–2022 (USD Million)
Table 113 RoAPAC: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 114 RoAPAC: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 115 RoAPAC: Market, By Platform, 2015–2022 (USD Million)
Table 116 RoAPAC: Market, By End User, 2015–2022 (USD Million)
Table 117 RoW: Point-of-Care Diagnostics Market, By Country, 2015–2022 (USD Million)
Table 118 RoW: Market, By Product, 2015–2022 (USD Million)
Table 119 RoW: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 120 RoW: Market, By Platform, 2015–2022 (USD Million)
Table 121 RoW: Market, By End User, 2015–2022 (USD Million)
Table 122 Latin America: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 123 Latin America: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 124 Latin America: Market, By Platform, 2015–2022 (USD Million)
Table 125 Latin America: Market, By End User, 2015–2022 (USD Million)
Table 126 Middle East & Africa: Point-of-Care Diagnostics Market, By Product, 2015–2022 (USD Million)
Table 127 Middle East & Africa: Market, By Prescription Mode, 2015–2022 (USD Million)
Table 128 Middle East & Africa: Market, By Platform, 2015-2022 (USD Million)
Table 129 Middle East & Africa: Market, By End User, 2015–2022 (USD Million)

List of Figures:
Figure 1 Research Methodology Steps
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Data Triangulation
Figure 4 Global Point-of-Care Diagnostics Market, By Product, 2017 vs 2022
Figure 5 Global Rapid Diagnostic Market, By Prescription Mode, 2017 vs 2022
Figure 6 Global Market, By Platform, 2017 vs 2022
Figure 7 Global Rapid Diagnostic Market, By End User, 2017 vs 2022
Figure 8 Global Market, By Region, 2017 (USD Million)
Figure 9 High Prevalence of Infectious Diseases is Driving the Adoption of POC Devices Across the Globe
Figure 10 Lateral Flow Assays Segment Will Continue to Dominate the Market in 2022
Figure 11 Professional Diagnostic Centers Segment to Dominate the Global POC Diagnostics End-User Market in 2017
Figure 12 Glucose Monitoring Segment to Dominate the POC Diagnostics Products Market During the Forecast Period
Figure 13 Prescription-Based Testing Products to Dominate the POC Diagnostics Market During the Forecast Period
Figure 14 North America to Register the Highest CAGR During the Forecast Period
Figure 15 POC Diagnostics Market: Drivers, Restraints, Opportunities, and Challenges
Figure 16 Estimated Number of Diabetic Patients, By Region, 2015 vs 2040
Figure 17 The Infectious Disease Testing Products Segment is Projected to Grow at the Highest CAGR During the Forecast Period
Figure 18 Molecular Diagnostics Segment to Witness Highest Growth Rate During the Forecast Period
Figure 19 OTC Testing Segment to Witness Higher Growth During the Forecast Period
Figure 20 Home Care to Witness Highest Growth During the Forecast Period
Figure 21 Rapid Diagnostic Market: Growth Forecast, By Region (2017–2022)
Figure 22 North America: Rapid Diagnostic Market Snapshot
Figure 23 Europe: Rapid Diagnostic Market Snapshot
Figure 24 APAC: Rapid Diagnostic Market Snapshot
Figure 25 Key Developments By Leading Market Players in the Market, 2015–2017
Figure 26 Point-of-Care Diagnostics Market Share, By Key Players, 2016
Figure 27 Abbott Laboratories: Company Snapshot
Figure 28 BD: Company Snapshot
Figure 29 Chembio Diagnostics: Company Snapshot
Figure 30 Danaher Corporation: Company Snapshot
Figure 31 EKF Diagnostics: Company Snapshot
Figure 32 Johnson & Johnson: Company Snapshot
Figure 33 Quidel: Company Snapshot
Figure 34 Roche Diagnostics: Company Snapshot
Figure 35 Siemens: Company Snapshot
Figure 36 Trinity Biotech: Company Snapshot

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Accubiotech
  • Chembio Diagnostics
  • Danaher Corporation
  • EKF Diagnostics
  • Johnson & Johnson
  • MORE

The global point-of-care diagnostics market is projected to reach USD 38.13 Billion by 2022 from USD 23.71 Billion in 2017, at a CAGR of 10.0% during the forecast period. Factors such as high prevalence of infectious diseases in developing countries, increasing incidence of target diseases, and rising preference for home healthcare across the globe are increasing the adoption of POC diagnostic products globally.

This report broadly segments the rapid diagnostic market into product, platform, mode, end user, and region.

On the basis of product, the global POC diagnostics market is segmented into products for glucose monitoring, infectious disease testing, coagulation testing, cardiometabolic testing, hematology testing, urinalysis testing, cholesterol testing, drugs of abuse testing, tumor/cancer marker testing, pregnancy and fertility testing, fecal occult testing, and others (multi-assay testing, liver testing, hepatitis A & B testing, and vitamin assay testing). The infectious disease testing products segment is expected to grow at the highest CAGR during the forecast period. The growing patient population base and increasing availability and awareness about infectious disease POC testing products are the major factors contributing to the segment’s growth.

Based on platforms, the point-of-care diagnostics market is further segmented into lateral flow assays, immunoassays, POC molecular diagnostics, dipsticks, and microfluidics. The molecular diagnostics segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to the growing advancements in technology, increasing initiatives of market players for developing POC molecular diagnostic products, and resource-limited settings.

On the basis of mode of prescription, the rapid diagnostic market is categorized into two segments prescription-based testing and OTC testing. The prescription-based testing segment is expected to command the largest share of the global point-of-care diagnostics market in 2017. The growth of this segment can be attributed to the increasing incidence and prevalence of lifestyle diseases and the lack of awareness on OTC POCT devices in developing nations.

On the basis of end user, the rapid diagnostic market is further segmented into professional diagnostic centers, home care, research laboratories, and other end users. The home care settings segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing preference for home and remote monitoring and rising demand for rapid tests among home care users.

The report covers the point-of-care diagnostics market across four major geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to command the largest share of the market in 2017, due to the growing prevalence of lifestyle diseases, increasing number of product approvals, and rising government initiatives in this region.

The major players of the market are Abbott (US), Roche (Switzerland), Siemens (Germany), Danaher (US), Becton, Dickinson, and Company (US), Johnson & Johnson (US), Instrumentation Laboratory (US), PTS Diagnostics (US), Quidel (US), Chembio (US), Sekisui Diagnostics (US), Nova (US), EKF Diagnostics (UK), AccuBioTech (China), and Trinity Biotech (US).

Note: Product cover images may vary from those shown
5 of 4
  • Abbott Laboratories
  • Accubiotech
  • Becton, Dickinson, and Company (BD)
  • Chembio Diagnostics
  • Danaher Corporation
  • EKF Diagnostics
  • Instrumentation Laboratory (A Werfen Company)
  • Johnson & Johnson
  • Nova Biomedical
  • PTS Diagnostics (A Part of Sinocare Inc.)
  • Quidel
  • Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche Ltd.)
  • Sekisui Diagnostics
  • Siemens
  • Trinity Biotech
Note: Product cover images may vary from those shown
6 of 4
Note: Product cover images may vary from those shown
Adroll
adroll